NeuroPace drops SEEG distribution deal to focus on core RNS System; reaffirms 2025 guidance

NeuroPace Inc

Terminated exclusive DIXI Medical SEEG distribution; wind down begins Q4 2025 through Q1 2026.
CEO cites strategic refocus on RNS System; expects growth from Project CARE, indication expansions, AI software.
Maintaining 2025 revenue guidance; no change to long-range plan of 20%+ CAGR and cash flow breakeven by end of 2027.
Gross margin expected to improve: SEEG margin ~50% vs. RNS margin >78%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.